Cargando…
Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study
BACKGROUND: The treatment outcome of transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (HCC) varies greatly due to the clinical heterogeneity of the patients. Therefore, several prognostic systems have been proposed for risk stratification and candidate identification f...
Autores principales: | Wang, Zhe-Xuan, Wang, En-Xin, Bai, Wei, Xia, Dong-Dong, Mu, Wei, Li, Jing, Yang, Qiao-Yi, Huang, Ming, Xu, Guo-Hui, Sun, Jun-Hui, Li, Hai-Liang, Zhao, Hui, Wu, Jian-Bing, Yang, Shu-Fa, Li, Jia-Ping, Li, Zi-Xiang, Zhang, Chun-Qing, Zhu, Xiao-Li, Zheng, Yan-Bo, Wang, Qiu-He, Yuan, Jie, Li, Xiao-Mei, Niu, Jing, Yin, Zhan-Xin, Xia, Jie-Lai, Fan, Dai-Ming, Han, Guo-Hong, on behalf of China HCC-TACE Study Group |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029354/ https://www.ncbi.nlm.nih.gov/pubmed/32103874 http://dx.doi.org/10.3748/wjg.v26.i6.657 |
Ejemplares similares
-
Prognostic role of ABO blood group in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization
por: Li, Qing, et al.
Publicado: (2018) -
Plasma arginase-1 as a predictive marker for early transarterial chemoembolization refractoriness in unresectable hepatocellular carcinoma
por: Xia, Wei-Li, et al.
Publicado: (2022) -
Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization
por: Wang, Zhe-Xuan, et al.
Publicado: (2020) -
Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma with Child-Pugh B7
por: Jiang, Jian-Qiang, et al.
Publicado: (2023) -
Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2020)